Evidence map›Paper›PMID 41618509›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2026

Psychiatric Disorders and Apathy in Mixed Movement Disorders Linked to ADCY5 (MxMD-ADCY5).

Aurélie Méneret, Clément Tarrano, Asya Ekmen, Diane Doummar, Victoria Gonzalez, Christine Tranchant, Mathieu Anheim, Philippe Damier, Eoin Mulroy, Kailash P Bhatia and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Distinct Brain Drivers and Shared Cerebello-Cortical Input in ADCY5 and SGCE Hyperkinetic Movements.Movement disorders : official journal of the Movement Disorder Society · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Aurélie MéneretDepartment of Neurology, DMU Neurosciences, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.ORCID https://orcid.org/0000-0002-7623-1142
Clément TarranoSorbonne University, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Asya EkmenSorbonne University, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Diane DoummarDepartment of Pediatric Neurology, Armand Trousseau Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Victoria GonzalezDepartment of Neurology, Vall d'Hebron University Hospital, Barcelona, Spain.
Christine TranchantDepartment of Neurology, University Hospital of Strasbourg, Hautepierre Hospital, Strasbourg, France.
Mathieu AnheimDepartment of Neurology, University Hospital of Strasbourg, Hautepierre Hospital, Strasbourg, France.
Philippe DamierDepartment of Neurology, University Hospital of Nantes, Nantes University, Nantes, France.ORCID https://orcid.org/0000-0003-3869-0564
Eoin MulroyDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Kailash P BhatiaDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Laura CifDépartement de Neurochirurgie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
Carlo FuscoMaternal and Child Department, Neurology and Psychiatry Unit, Azienda USL-IRCCS of Reggio Emilia, Reggio Emilia, Italy.
Miryam CarecchioParkinson and Movement Disorders Unit, Department of Neuroscience, University of Padova, Padua, Italy.
Norbert BrüggemannInstitute of Neurogenetics, University of Lübeck, Lübeck, Germany.
Alexander MünchauInstitute of Systems Motor Science, University of Lübeck, CBBM, Lübeck, Germany.ORCID https://orcid.org/0000-0002-3219-2284
Florence RiantMolecular Neurogenetics Unit, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Manon GomesClinical Investigation Center for Neurosciences, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Vanessa BrochardClinical Investigation Center for Neurosciences, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Agathe RoubertieService de Neuropédiatrie, CHU Montpellier, Montpellier, France.
Oriane TrouillardSorbonne University, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.ORCID https://orcid.org/0000-0003-0228-0942
Caroline DubacqSorbonne University, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Yulia WorbeDepartment of Neurology, DMU Neurosciences, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Mohamed DoulazmiSorbonne Université, CNRS, INSERM, NeuroSU, Paris, France.
Emmanuel RozeDepartment of Neurology, DMU Neurosciences, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

Funding

adcy5.orgAgence Nationale de la Recherche ANR-16-CE37-0003-03AMADYSFondation pour la Recherche Médicale FDM202106013364Horizon 2020 Framework Programme COFUND-EJP N825575-EurDyscoveriCRIN program of the Paris Brain InstituteMerz Pharmaceuticals
6 · The paper itself

Abstract

backgroundMixed movement disorders linked to ADCY5 (MxMD-ADCY5) represent a rare hyperkinetic movement disorder resulting from pathogenic variants in ADCY5. Psychiatric symptoms are suspected to be part of the phenotype.

objectiveThe study aim was to assess psychiatric comorbidities in patients with MxMD-ADCY5.

methodsConsecutive patients were assessed with the MINI International Neuropsychiatric Interview (MINI), the shortened Beck Depression Inventory (BDI-13), the Hospital Anxiety and Depression Scale (HADS), and the Starkstein Apathy Scale (SAS).

resultsTwenty-seven patients and 20 controls were included. Psychiatric disorders were present in 67% of patients compared with 15% of controls (P = 0.00043), mainly anxiety (33% vs. 0%, P = 0.00862) and depression (44% vs. 10%, P = 0.01068). Depression, anxiety, and apathy scores were higher in patients (BDI-13: 3.67 vs. 1.05, P = 0.004; HA: 6.71 vs. 3.90, P = 0.006; AS: 11.67 vs. 6.85, P = 0.001).

conclusionDepression, anxiety, and apathy are likely part of the phenotypic spectrum of MxMD-ADCY5. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Indexed as

Adenylyl CyclasesApathyMental DisordersMovement DisordersAdultAgedAnxietyDepressionFemaleHumansMaleMiddle AgedPsychiatric Status Rating ScalesAdenylyl Cyclasesadenylyl cyclase type VADCY5anxietyapathydepressiondyskinesiadystoniapsychiatric

Identifiers

PMID41618509
PMCPMC13206175

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.